Quoin Pharmaceuticals Ltd ADR (NASDAQ: QNRX) kicked off on Monday, down -3.99% from the previous trading day, before settling in for the closing price of $0.31. Over the past 52 weeks, QNRX has traded in a range of $0.28-$6.18.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 78.42%. With a float of $5.03 million, this company’s outstanding shares have now reached $5.05 million.
Let’s determine the extent of company efficiency that accounts for 4 employees. In terms of profitability, gross margin is 50.81%, operating margin of -5948.33%, and the pretax margin is -5648.18%.
Quoin Pharmaceuticals Ltd ADR (QNRX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Quoin Pharmaceuticals Ltd ADR is 0.31%, while institutional ownership is 4.92%. The most recent insider transaction that took place on Dec 23 ’24, was worth 250,000. In this transaction Chief Operating Officer of this company bought 555,556 shares at a rate of $0.45, taking the stock ownership to the 602,648 shares. Before that another transaction happened on Dec 23 ’24, when Company’s Chief Executive Officer bought 555,556 for $0.45, making the entire transaction worth $250,000. This insider now owns 602,808 shares in total.
Quoin Pharmaceuticals Ltd ADR (QNRX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 78.42% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 82.69% during the next five years compared to -194.79% drop over the previous five years of trading.
Quoin Pharmaceuticals Ltd ADR (NASDAQ: QNRX) Trading Performance Indicators
Take a look at Quoin Pharmaceuticals Ltd ADR’s (QNRX) current performance indicators. Last quarter, stock had a quick ratio of 3.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.08, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -1.48 in one year’s time.
Technical Analysis of Quoin Pharmaceuticals Ltd ADR (QNRX)
Looking closely at Quoin Pharmaceuticals Ltd ADR (NASDAQ: QNRX), its last 5-days average volume was 11.08 million, which is a jump from its year-to-date volume of 5.35 million. As of the previous 9 days, the stock’s Stochastic %D was 16.96%. Additionally, its Average True Range was 0.07.
During the past 100 days, Quoin Pharmaceuticals Ltd ADR’s (QNRX) raw stochastic average was set at 1.54%, which indicates a significant decrease from 5.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 167.82% in the past 14 days, which was higher than the 146.19% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5607, while its 200-day Moving Average is $0.6262. However, in the short run, Quoin Pharmaceuticals Ltd ADR’s stock first resistance to watch stands at $0.3129. Second resistance stands at $0.3248. The third major resistance level sits at $0.3363. If the price goes on to break the first support level at $0.2895, it is likely to go to the next support level at $0.2780. Now, if the price goes above the second support level, the third support stands at $0.2661.
Quoin Pharmaceuticals Ltd ADR (NASDAQ: QNRX) Key Stats
The company with the Market Capitalisation of 1.52 million has total of 5,050K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -8,690 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -2,350 K.
